AstraZeneca AZD6234 Amylin Peptide Agonist Phase 2 Data Queued for EASD 2026 in Rome September 28 to October 2
AstraZeneca's AZD6234 (a long-acting selective amylin receptor peptide agonist, weekly subcutaneous, currently in Phase 2 for obesity and type 2 diabetes) is queued for Phase 2 data presentations at the European Association for the Study of Diabetes (EASD) 61st Annual Meeting in Rome September 28 to October 2, 2026. Trials on deck: APRICUS (obesity monotherapy) primary data 'imminent' per management; ARAY (NCT06851858, AZD6234 in obesity and type 2 diabetes on stable GLP-1 background); and the ASCEND Phase 2b (NCT06862791, 377 patients) that tests AZD6234 monotherapy, AZD9550 (AZ's GLP-1/glucagon dual agonist) monotherapy, and the combination against placebo over 36 weeks. Preliminary characterization suggests body-fat-selective weight loss and a generally tolerable profile. The readouts will provide a direct comparator against Novo Nordisk's CagriSema (semaglutide plus cagrilintide) and Metsera's MET-233i (monthly amylin) and set the near-term valuation frame for AZ's metabolic disease positioning after the $1.2 billion CSPC obesity licensing announced in January.